252 related articles for article (PubMed ID: 31254596)
1. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
3. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.
Walters JR; Johnston IM; Nolan JD; Vassie C; Pruzanski ME; Shapiro DA
Aliment Pharmacol Ther; 2015 Jan; 41(1):54-64. PubMed ID: 25329562
[TBL] [Abstract][Full Text] [Related]
4. Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19.
Barrera F; Azócar L; Molina H; Schalper KA; Ocares M; Liberona J; Villarroel L; Pimentel F; Pérez-Ayuso RM; Nervi F; Groen AK; Miquel JF
Ann Hepatol; 2015; 14(5):710-21. PubMed ID: 26256900
[TBL] [Abstract][Full Text] [Related]
5. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
[TBL] [Abstract][Full Text] [Related]
6. An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers.
Al-Khaifi A; Rudling M; Angelin B
Gastroenterology; 2018 Oct; 155(4):1012-1016. PubMed ID: 29928896
[TBL] [Abstract][Full Text] [Related]
7. Triglycerides and gallstone formation.
Smelt AH
Clin Chim Acta; 2010 Nov; 411(21-22):1625-31. PubMed ID: 20699090
[TBL] [Abstract][Full Text] [Related]
8. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
Siddiqui MS; Van Natta ML; Connelly MA; Vuppalanchi R; Neuschwander-Tetri BA; Tonascia J; Guy C; Loomba R; Dasarathy S; Wattacheril J; Chalasani N; Sanyal AJ;
J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study.
Appleby RN; Moghul I; Khan S; Yee M; Manousou P; Neal TD; Walters JRF
PLoS One; 2019; 14(1):e0211348. PubMed ID: 30682184
[TBL] [Abstract][Full Text] [Related]
10. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
11. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
12. Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.
Zweers SJ; de Vries EM; Lenicek M; Tolenaars D; de Waart DR; Koelfat KV; Groen AK; Olde Damink SW; Beuers U; Ponsioen C; Jansen PL; Schaap FG
Hepatol Int; 2017 Jan; 11(1):132-140. PubMed ID: 27696157
[TBL] [Abstract][Full Text] [Related]
13. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
Fiorucci S; Di Giorgio C; Distrutti E
Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
[TBL] [Abstract][Full Text] [Related]
14. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
Friedrich D; Marschall HU; Lammert F
BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
[TBL] [Abstract][Full Text] [Related]
15. Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid.
de Haan LR; Verheij J; van Golen RF; Horneffer-van der Sluis V; Lewis MR; Beuers UHW; van Gulik TM; Olde Damink SWM; Schaap FG; Heger M; Olthof PB
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33578971
[No Abstract] [Full Text] [Related]
16. Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis.
van Schaik FD; Gadaleta RM; Schaap FG; van Mil SW; Siersema PD; Oldenburg B; van Erpecum KJ
PLoS One; 2012; 7(11):e49706. PubMed ID: 23189156
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
[TBL] [Abstract][Full Text] [Related]
19. Effect of obeticholic acid on liver regeneration following portal vein embolization in an experimental model.
Olthof PB; Huisman F; Schaap FG; van Lienden KP; Bennink RJ; van Golen RF; Heger M; Verheij J; Jansen PL; Olde Damink SW; van Gulik TM
Br J Surg; 2017 Apr; 104(5):590-599. PubMed ID: 28195307
[TBL] [Abstract][Full Text] [Related]
20. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids.
Zhang JH; Nolan JD; Kennie SL; Johnston IM; Dew T; Dixon PH; Williamson C; Walters JR
Am J Physiol Gastrointest Liver Physiol; 2013 May; 304(10):G940-8. PubMed ID: 23518683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
